Skip to main content
Equibles
TGTX logo

TGTX · Tg Therapeutics, Inc. · Metrics

Track TGTX — free

Use TGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$53.89 -1.50 (-2.71%) At close · Sep 11
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$8.25B
Shares
153.07M

TGTX metrics

77 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$53.89
Market cap
$8.25B

Price action

20 metrics
Price change (1W)
-3.7%
Price change (30D)
+10.6%
Price change (3M)
+8.8%
Price change (6M)
+92.7%
Price change (YTD)
+80.8%
Price change (1Y)
+66.0%
Trailing year
Price change (5Y)
+80.9%
52-week high
$59.06
52-week low
$26.94
Change from 52-week high
-8.8%
Change from 52-week low
+100.0%
Annualized volatility
45.6%
Annualized volatility (3M)
45.3%
Beta
0.6
RSI (14D)
50.0
Price vs SMA 50
+0.6%
Price vs SMA 200
+36.4%
Avg volume (3M)
2.34M
Relative volume
0.6
Average dollar volume
$124.64M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
153.07M

Valuation

12 metrics
P / E (TTM)
19.7
Trailing earnings · reciprocal yield 5.1%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
10.3×
reciprocal yield 9.7%
P / book
13.7
reciprocal yield 7.3%
FCF yield
0.2%
TTM · current market cap
Buyback yield
0.0%
P / FCF
474.5
reciprocal yield 0.2%
P / operating cash flow
461.5
reciprocal yield 0.2%
Earnings yield
5.4%

Historical valuation

8 metrics
P / E historical average (3Y)
43.5×
reciprocal yield 2.3%
P / E historical average (5Y)
43.5×
reciprocal yield 2.3%
EV / revenue historical average (3Y)
473.3×
reciprocal yield 0.2%
EV / revenue historical average (5Y)
5,608.9×
reciprocal yield 0.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
82.4%
Operating margin
17.1%
Trailing 12 months
Net margin
55.2%
Gross profit (TTM)
—
Operating profit (TTM)
$136.33M
Net income (TTM)
$441.49M
Trailing 12 months
Diluted EPS (TTM)
$2.74
FCF margin
2.2%
Effective tax rate
-334.5%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.17

Growth

11 metrics
Revenue growth YoY
+70.3%
Year over year
Net income growth YoY
-72.4%
Revenue (TTM)
$799.54M
Trailing 12 months
EPS growth YoY
-70.6%
Shares change YoY
-3.2%
Year over year · fewer shares
Revenue CAGR (3Y)
+504.9%
Revenue CAGR (5Y)
+426.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
73.1%
Return on assets
26.9%
Debt / equity
—
Current ratio
4.3
EBITDA (TTM)
$136.45M
Free cash flow (TTM)
$17.39M
Quick ratio
3.7
Interest coverage
3.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$482.57M
Total assets
$1.64B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$17.88M
Capital expenditures (TTM)
$491,000
R&D (TTM)
$225.80M
SG&A (TTM)
$296.46M
Stock compensation (TTM)
$81.16M
R&D / revenue
28.2%
Stock compensation / revenue
10.2%

Ownership (13F)

3 metrics
13F filers
433
13F filer change QoQ
+64
Institutional ownership
75.2%

Short interest

3 metrics
Short interest
19.7%
Latest settlement · 15.9 days to cover
Days to cover
15.9d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1001316 CUSIP 88322Q108 13F (30d) 101 filings 100 filers Visit website Investor relations